Toolkit/cLIPS2

cLIPS2

Multi-Component Switch·Research·Since 2019

Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.

Summary

cLIPS2 is a light-responsive multi-component switch identified from small libraries of cLIPS1 variants in a higher-throughput yeast screen. It binds human eIF4E in a light-dependent manner in vitro and inhibits translation in vivo in yeast harboring human eIF4E, with improved optical control relative to screened cLIPS1 variants.

Usefulness & Problems

Why this is useful

cLIPS2 is useful as an optogenetic regulator of eukaryotic translation initiation because it enables light-dependent engagement of human eIF4E and corresponding inhibition of translation in yeast. The reported improved degree of optical control suggests value for experiments requiring tighter light responsiveness than the screened cLIPS1 variants provided.

Source:

We identified cLIPS1 (circularly permuted LOV inhibitor of protein synthesis 1), a fusion of a segment of 4EBP2 and a circularly permuted version of the LOV2 domain from Avena sativa, as a photoactivated inhibitor of translation.

Source:

We show that these constructs can both inhibit translation in yeast harboring a human eIF4E in vivo

Problem solved

cLIPS2 helps address the problem of achieving externally controllable inhibition of translation initiation through human eIF4E. The source specifically positions it as a product of a yeast discovery system for optogenetic inhibitors of eukaryotic translation initiation and a higher-throughput screen for improved optical control.

Problem links

supports analysis of local translation with improved spatial and temporal resolution

Literature

It addresses the need to resolve local translation events in space and time rather than treating protein synthesis as a bulk process.

Source:

It addresses the need to resolve local translation events in space and time rather than treating protein synthesis as a bulk process.

Taxonomy & Function

Primary hierarchy

Mechanism Branch

Architecture: A composed arrangement of multiple parts that instantiates one or more mechanisms.

Target processes

recombinationselectiontranslation

Input: Light

Implementation Constraints

cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: multi component delivery burdenimplementation constraint: payload burdenimplementation constraint: spectral hardware requirementoperating role: regulatorswitch architecture: multi component

cLIPS2 was identified by adapting the yeast screen to higher throughput and testing small libraries of cLIPS1 variants. The available evidence indicates use in yeast harboring human eIF4E and dependence on light input, but it does not specify construct composition, cofactors, expression details, or delivery strategy.

The supplied evidence does not provide quantitative performance metrics, domain architecture, illumination wavelength, dynamic range, or kinetic parameters for cLIPS2. Validation is limited to in vitro binding and yeast-based in vivo translation inhibition, with no independent replication provided here.

Validation

Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication

Observations

successYeastapplication demo

Inferred from claim c4 during normalization. cLIPS1 and cLIPS2 can inhibit translation in yeast harboring human eIF4E in vivo. Derived from claim c4. Quoted text: We show that these constructs can both inhibit translation in yeast harboring a human eIF4E in vivo

Source:

successYeastapplication demo

Inferred from claim c4 during normalization. cLIPS1 and cLIPS2 can inhibit translation in yeast harboring human eIF4E in vivo. Derived from claim c4. Quoted text: We show that these constructs can both inhibit translation in yeast harboring a human eIF4E in vivo

Source:

successYeastapplication demo

Inferred from claim c4 during normalization. cLIPS1 and cLIPS2 can inhibit translation in yeast harboring human eIF4E in vivo. Derived from claim c4. Quoted text: We show that these constructs can both inhibit translation in yeast harboring a human eIF4E in vivo

Source:

successYeastapplication demo

Inferred from claim c4 during normalization. cLIPS1 and cLIPS2 can inhibit translation in yeast harboring human eIF4E in vivo. Derived from claim c4. Quoted text: We show that these constructs can both inhibit translation in yeast harboring a human eIF4E in vivo

Source:

successYeastapplication demo

Inferred from claim c4 during normalization. cLIPS1 and cLIPS2 can inhibit translation in yeast harboring human eIF4E in vivo. Derived from claim c4. Quoted text: We show that these constructs can both inhibit translation in yeast harboring a human eIF4E in vivo

Source:

successYeastapplication demo

Inferred from claim c4 during normalization. cLIPS1 and cLIPS2 can inhibit translation in yeast harboring human eIF4E in vivo. Derived from claim c4. Quoted text: We show that these constructs can both inhibit translation in yeast harboring a human eIF4E in vivo

Source:

successYeastapplication demo

Inferred from claim c4 during normalization. cLIPS1 and cLIPS2 can inhibit translation in yeast harboring human eIF4E in vivo. Derived from claim c4. Quoted text: We show that these constructs can both inhibit translation in yeast harboring a human eIF4E in vivo

Source:

Supporting Sources

Ranked Claims

Claim 1method capability summarysupports2022Source 2needs review

According to the supplied summary of the review, TRAP has been used to determine translation snapshots following learning, retrieval, and extinction.

Claim 2method use case summarysupports2022Source 2needs review

The review explicitly discusses ciPSI, gePSI, cLIPS2, TRAP, and RiboTag as relevant methods for interrogating local or cell-type-specific protein synthesis in memory-related contexts.

Claim 3review scope summarysupports2022Source 2needs review

The review frames spatiotemporally resolved protein synthesis and translational control as a molecular framework for memory consolidation.

Claim 4binding activitysupports2019Source 1needs review

cLIPS1 and cLIPS2 bind human eIF4E in vitro in a light-dependent manner.

and bind human eIF4E in vitro in a light-dependent manner.
Claim 5binding activitysupports2019Source 1needs review

cLIPS1 and cLIPS2 bind human eIF4E in vitro in a light-dependent manner.

and bind human eIF4E in vitro in a light-dependent manner.
Claim 6binding activitysupports2019Source 1needs review

cLIPS1 and cLIPS2 bind human eIF4E in vitro in a light-dependent manner.

and bind human eIF4E in vitro in a light-dependent manner.
Claim 7binding activitysupports2019Source 1needs review

cLIPS1 and cLIPS2 bind human eIF4E in vitro in a light-dependent manner.

and bind human eIF4E in vitro in a light-dependent manner.
Claim 8binding activitysupports2019Source 1needs review

cLIPS1 and cLIPS2 bind human eIF4E in vitro in a light-dependent manner.

and bind human eIF4E in vitro in a light-dependent manner.
Claim 9binding activitysupports2019Source 1needs review

cLIPS1 and cLIPS2 bind human eIF4E in vitro in a light-dependent manner.

and bind human eIF4E in vitro in a light-dependent manner.
Claim 10binding activitysupports2019Source 1needs review

cLIPS1 and cLIPS2 bind human eIF4E in vitro in a light-dependent manner.

and bind human eIF4E in vitro in a light-dependent manner.
Claim 11functional activitysupports2019Source 1needs review

cLIPS1 is a photoactivated inhibitor of translation.

We identified cLIPS1 (circularly permuted LOV inhibitor of protein synthesis 1), a fusion of a segment of 4EBP2 and a circularly permuted version of the LOV2 domain from Avena sativa, as a photoactivated inhibitor of translation.
Claim 12functional activitysupports2019Source 1needs review

cLIPS1 is a photoactivated inhibitor of translation.

We identified cLIPS1 (circularly permuted LOV inhibitor of protein synthesis 1), a fusion of a segment of 4EBP2 and a circularly permuted version of the LOV2 domain from Avena sativa, as a photoactivated inhibitor of translation.
Claim 13functional activitysupports2019Source 1needs review

cLIPS1 is a photoactivated inhibitor of translation.

We identified cLIPS1 (circularly permuted LOV inhibitor of protein synthesis 1), a fusion of a segment of 4EBP2 and a circularly permuted version of the LOV2 domain from Avena sativa, as a photoactivated inhibitor of translation.
Claim 14functional activitysupports2019Source 1needs review

cLIPS1 is a photoactivated inhibitor of translation.

We identified cLIPS1 (circularly permuted LOV inhibitor of protein synthesis 1), a fusion of a segment of 4EBP2 and a circularly permuted version of the LOV2 domain from Avena sativa, as a photoactivated inhibitor of translation.
Claim 15functional activitysupports2019Source 1needs review

cLIPS1 is a photoactivated inhibitor of translation.

We identified cLIPS1 (circularly permuted LOV inhibitor of protein synthesis 1), a fusion of a segment of 4EBP2 and a circularly permuted version of the LOV2 domain from Avena sativa, as a photoactivated inhibitor of translation.
Claim 16functional activitysupports2019Source 1needs review

cLIPS1 is a photoactivated inhibitor of translation.

We identified cLIPS1 (circularly permuted LOV inhibitor of protein synthesis 1), a fusion of a segment of 4EBP2 and a circularly permuted version of the LOV2 domain from Avena sativa, as a photoactivated inhibitor of translation.
Claim 17functional activitysupports2019Source 1needs review

cLIPS1 is a photoactivated inhibitor of translation.

We identified cLIPS1 (circularly permuted LOV inhibitor of protein synthesis 1), a fusion of a segment of 4EBP2 and a circularly permuted version of the LOV2 domain from Avena sativa, as a photoactivated inhibitor of translation.
Claim 18in vivo activitysupports2019Source 1needs review

cLIPS1 and cLIPS2 can inhibit translation in yeast harboring human eIF4E in vivo.

We show that these constructs can both inhibit translation in yeast harboring a human eIF4E in vivo
Claim 19in vivo activitysupports2019Source 1needs review

cLIPS1 and cLIPS2 can inhibit translation in yeast harboring human eIF4E in vivo.

We show that these constructs can both inhibit translation in yeast harboring a human eIF4E in vivo
Claim 20in vivo activitysupports2019Source 1needs review

cLIPS1 and cLIPS2 can inhibit translation in yeast harboring human eIF4E in vivo.

We show that these constructs can both inhibit translation in yeast harboring a human eIF4E in vivo
Claim 21in vivo activitysupports2019Source 1needs review

cLIPS1 and cLIPS2 can inhibit translation in yeast harboring human eIF4E in vivo.

We show that these constructs can both inhibit translation in yeast harboring a human eIF4E in vivo
Claim 22in vivo activitysupports2019Source 1needs review

cLIPS1 and cLIPS2 can inhibit translation in yeast harboring human eIF4E in vivo.

We show that these constructs can both inhibit translation in yeast harboring a human eIF4E in vivo
Claim 23in vivo activitysupports2019Source 1needs review

cLIPS1 and cLIPS2 can inhibit translation in yeast harboring human eIF4E in vivo.

We show that these constructs can both inhibit translation in yeast harboring a human eIF4E in vivo
Claim 24in vivo activitysupports2019Source 1needs review

cLIPS1 and cLIPS2 can inhibit translation in yeast harboring human eIF4E in vivo.

We show that these constructs can both inhibit translation in yeast harboring a human eIF4E in vivo
Claim 25optimization outcomesupports2019Source 1needs review

cLIPS2 has an improved degree of optical control relative to cLIPS1 variants screened.

Adapting the screen for higher throughput, we tested small libraries of cLIPS1 variants and found cLIPS2, a construct with an improved degree of optical control.
Claim 26optimization outcomesupports2019Source 1needs review

cLIPS2 has an improved degree of optical control relative to cLIPS1 variants screened.

Adapting the screen for higher throughput, we tested small libraries of cLIPS1 variants and found cLIPS2, a construct with an improved degree of optical control.
Claim 27optimization outcomesupports2019Source 1needs review

cLIPS2 has an improved degree of optical control relative to cLIPS1 variants screened.

Adapting the screen for higher throughput, we tested small libraries of cLIPS1 variants and found cLIPS2, a construct with an improved degree of optical control.
Claim 28optimization outcomesupports2019Source 1needs review

cLIPS2 has an improved degree of optical control relative to cLIPS1 variants screened.

Adapting the screen for higher throughput, we tested small libraries of cLIPS1 variants and found cLIPS2, a construct with an improved degree of optical control.
Claim 29optimization outcomesupports2019Source 1needs review

cLIPS2 has an improved degree of optical control relative to cLIPS1 variants screened.

Adapting the screen for higher throughput, we tested small libraries of cLIPS1 variants and found cLIPS2, a construct with an improved degree of optical control.
Claim 30optimization outcomesupports2019Source 1needs review

cLIPS2 has an improved degree of optical control relative to cLIPS1 variants screened.

Adapting the screen for higher throughput, we tested small libraries of cLIPS1 variants and found cLIPS2, a construct with an improved degree of optical control.
Claim 31optimization outcomesupports2019Source 1needs review

cLIPS2 has an improved degree of optical control relative to cLIPS1 variants screened.

Adapting the screen for higher throughput, we tested small libraries of cLIPS1 variants and found cLIPS2, a construct with an improved degree of optical control.

Approval Evidence

2 sources5 linked approval claimsfirst-pass slug clips2
The web research summary states that the anchor review explicitly identifies cLIPS2 as an enabling method for studying local translation with high spatiotemporal resolution.

Source:

Adapting the screen for higher throughput, we tested small libraries of cLIPS1 variants and found cLIPS2, a construct with an improved degree of optical control.

Source:

method use case summarysupports

The review explicitly discusses ciPSI, gePSI, cLIPS2, TRAP, and RiboTag as relevant methods for interrogating local or cell-type-specific protein synthesis in memory-related contexts.

Source:

review scope summarysupports

The review frames spatiotemporally resolved protein synthesis and translational control as a molecular framework for memory consolidation.

Source:

binding activitysupports

cLIPS1 and cLIPS2 bind human eIF4E in vitro in a light-dependent manner.

and bind human eIF4E in vitro in a light-dependent manner.

Source:

in vivo activitysupports

cLIPS1 and cLIPS2 can inhibit translation in yeast harboring human eIF4E in vivo.

We show that these constructs can both inhibit translation in yeast harboring a human eIF4E in vivo

Source:

optimization outcomesupports

cLIPS2 has an improved degree of optical control relative to cLIPS1 variants screened.

Adapting the screen for higher throughput, we tested small libraries of cLIPS1 variants and found cLIPS2, a construct with an improved degree of optical control.

Source:

Comparisons

Source-stated alternatives

The supplied summary places cLIPS2 alongside ciPSI and gePSI as emerging tools, with TRAP and RiboTag as related profiling approaches.

Source:

The supplied summary places cLIPS2 alongside ciPSI and gePSI as emerging tools, with TRAP and RiboTag as related profiling approaches.

Source-backed strengths

The tool has evidence for both light-dependent in vitro binding to human eIF4E and in vivo translation inhibition in yeast harboring human eIF4E. It was also singled out from screened cLIPS1 variant libraries as having an improved degree of optical control.

Source:

Adapting the screen for higher throughput, we tested small libraries of cLIPS1 variants and found cLIPS2, a construct with an improved degree of optical control.

Compared with ciPSI

The supplied summary places cLIPS2 alongside ciPSI and gePSI as emerging tools, with TRAP and RiboTag as related profiling approaches.

Shared frame: source-stated alternative in extracted literature

Strengths here: explicitly described as enabling high spatiotemporal resolution.

Relative tradeoffs: the provided payload does not specify assay format, throughput, or biological constraints.

Source:

The supplied summary places cLIPS2 alongside ciPSI and gePSI as emerging tools, with TRAP and RiboTag as related profiling approaches.

The supplied summary places cLIPS2 alongside ciPSI and gePSI as emerging tools, with TRAP and RiboTag as related profiling approaches.

Shared frame: source-stated alternative in extracted literature

Strengths here: explicitly described as enabling high spatiotemporal resolution.

Relative tradeoffs: the provided payload does not specify assay format, throughput, or biological constraints.

Source:

The supplied summary places cLIPS2 alongside ciPSI and gePSI as emerging tools, with TRAP and RiboTag as related profiling approaches.

Compared with gePSI

The supplied summary places cLIPS2 alongside ciPSI and gePSI as emerging tools, with TRAP and RiboTag as related profiling approaches.

Shared frame: source-stated alternative in extracted literature

Strengths here: explicitly described as enabling high spatiotemporal resolution.

Relative tradeoffs: the provided payload does not specify assay format, throughput, or biological constraints.

Source:

The supplied summary places cLIPS2 alongside ciPSI and gePSI as emerging tools, with TRAP and RiboTag as related profiling approaches.

Compared with RiboTag

The supplied summary places cLIPS2 alongside ciPSI and gePSI as emerging tools, with TRAP and RiboTag as related profiling approaches.

Shared frame: source-stated alternative in extracted literature

Strengths here: explicitly described as enabling high spatiotemporal resolution.

Relative tradeoffs: the provided payload does not specify assay format, throughput, or biological constraints.

Source:

The supplied summary places cLIPS2 alongside ciPSI and gePSI as emerging tools, with TRAP and RiboTag as related profiling approaches.

Compared with TRAP

The supplied summary places cLIPS2 alongside ciPSI and gePSI as emerging tools, with TRAP and RiboTag as related profiling approaches.

Shared frame: source-stated alternative in extracted literature

Strengths here: explicitly described as enabling high spatiotemporal resolution.

Relative tradeoffs: the provided payload does not specify assay format, throughput, or biological constraints.

Source:

The supplied summary places cLIPS2 alongside ciPSI and gePSI as emerging tools, with TRAP and RiboTag as related profiling approaches.

Ranked Citations

  1. 1.
    StructuralSource 1ACS Synthetic Biology2019Claim 4Claim 5Claim 6

    Extracted from this source document.

  2. 2.
    StructuralSource 2Trends in Neurosciences2022Claim 1Claim 2Claim 3

    Seeded from load plan for claim cl1. Extracted from this source document.